5 Million Americans May Benefit if Psilocybin Approved for Depression

Over 5 million Americans could benefit if the U.S. Food and Drug Administration (FDA) approves the psychedelic psilocybin, derived from "magic mushrooms," as a treatment for depression, according to recent research. 

Dr. Charles Raison, a professor of psychiatry and human ecology at the University of Wisconsin in Madison, emphasized that their analysis is only the beginning of understanding the potential public health impact of psilocybin therapy. Psilocybin, once dismissed as an illegal drug, has recently seen renewed interest due to studies suggesting its potential in alleviating hard-to-treat depression when administered in a controlled and supervised environment. 

Currently under consideration by the FDA, psilocybin could become a new treatment option for depression. To gauge how many Americans might benefit, Raison and his colleagues analyzed national depression data and patient criteria from recent clinical trials. They estimated that between 56% and 62% of Americans receiving treatment for depression could be candidates for psilocybin therapy. This translates to approximately 5.1 million to 5.6 million potential patients.

The number of eligible patients could increase if individuals who are not currently receiving treatment for their depression decide to opt for psilocybin therapy. This highlights the need to understand the practical aspects of implementing this novel treatment on a large scale, noted Syed Fayzan Rab, the study's lead author and an MD candidate at Emory University's medical school in Atlanta.

Published on September 13 in the journal Psychedelics, the study also pointed out that many potential candidates for psilocybin therapy might have substance abuse issues. The treatment is increasingly seen as beneficial for such patients.

However, the number of people who might turn to psilocybin would also depend on the FDA's guidelines regarding who should and should not use the drug. Factors such as insurance coverage for psilocybin therapy and the availability of trained professionals to administer the treatment would also play crucial roles.

Ultimately, the effectiveness of this treatment in real-world settings will depend on regulatory bodies, policymakers, insurers, and the broader healthcare community, Raison noted. He expressed hope that the findings would spur productive discussions and proactive preparations to optimize patient benefits while minimizing unintended consequences.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!